PSMA PET: Clinical Trials

17 trials of PSMA PET, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 4 not yet recruiting, 4 terminated, 3 active not recruiting. 17 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Recruiting 5, Not yet recruiting 4, Terminated 4, Active not recruiting 3, Completed 1
Phase 31Recruiting 1

Follow PSMA PET: new trials by email Literature Review of PSMA PET trials Research Report on PSMA PET

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer
Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2Not yet recruitingNational Cancer Institute (NCI)242027-02-262026-11-12
PSMA PET/MRI for Predicting and Detecting Prostate Cancer
PSMA PET, MRI, 18F-DCFPyL - Prostate Cancer, High-Risk Localized Prostate Cancer
Phase 2Not yet recruitingUniversity of Wisconsin, Madison1202026-12-012026-11-09
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2RecruitingUniversity of Washington642026-11-152026-10-19
Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2Not yet recruitingEmory University882026-11-022026-10-06
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Radium-223, PSMA Positron Emission Tomography (PET) Scan, Technetium Tc 99M Medronate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Phase 2Active not recruitingUniversity of California, San Francisco22024-08-302026-01-14
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan - Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Phase 2RecruitingJonsson Comprehensive Cancer Center902024-08-012026-03-10
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Phase 2TerminatedUniversity of Washington82024-05-232026-10-19
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Biospecimen Collection, Carboplatin, Chest Radiography - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Phase 2RecruitingSWOG Cancer Research Network442024-03-012026-01-29
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
Biospecimen Collection, Bone Scan, Brachytherapy - Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Phase 2Not yet recruitingUniversity of Kansas Medical Center902023-11-202023-11-13
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Phase 2TerminatedThomas Jefferson University62022-11-162026-03-03
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Phase 2Active not recruitingNRG Oncology1942022-04-202026-08-17
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Phase 2Active not recruitingMayo Clinic452021-07-232026-06-04
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
PET Scan, [18F]PSMA-1007 Injection, Sodium MRI - Prostate Cancer, Prostate Adenocarcinoma
Phase 2CompletedGlenn Bauman162021-02-042026-09-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Positron Emission Tomography, Lymphadenectomy, Radiation Therapy - Prostate Adenocarcinoma
Phase 2RecruitingUniversity of Washington1002020-09-302026-07-07
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
F-DCFPyL Injection, PSMA PET - Prostate Cancer, Recurrent Prostate Cancer
Phase 2 / Phase 3RecruitingH. Lee Moffitt Cancer Center and Research Institute602019-12-182026-03-02
SUV on PSMA PET/CT in Non-Prostate Tumors
PSMA PET/CT - Cancer
Phase 2TerminatedSir Mortimer B. Davis - Jewish General Hospital32019-07-252023-04-12
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
PSMA-based 18F-DCFPyL PET tracer for PET/CT exams - Renal Cell Carcinoma
Phase 2TerminatedUniversity of Wisconsin, Madison52018-12-082022-12-21

Conditions studied

Prostatic Neoplasms (13)  ·  Carcinoma, Adenoid Cystic (1)  ·  Carcinoma, Renal Cell (1)  ·  Kidney Neoplasms (1)  ·  Neoplasms (1)  ·  Salivary Gland Neoplasms (1)

Sponsors

University of Washington (3)  ·  University of Wisconsin, Madison (2)  ·  Emory University (1)  ·  Glenn Bauman (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Mayo Clinic (1)  ·  NRG Oncology (1)  ·  National Cancer Institute (NCI) (1)  ·  SWOG Cancer Research Network (1)  ·  Sir Mortimer B. Davis - Jewish General Hospital (1)  ·  Thomas Jefferson University (1)  ·  University of California, San Francisco (1)  ·  University of Kansas Medical Center (1)

Countries

United States (14)  ·  Canada (3)

Top investigators

Adel Mandl (1)  ·  Ashish Chintakuntlawar, MBBS, PhD (1)  ·  Bridget F Koontz (1)  ·  Changhee Lee, MD (1)  ·  Evan Yu (1)  ·  Heather H Cheng (1)  ·  Jacob E Berchuck, MD (1)  ·  Jeremie Calais (1)  ·  Jessie DiNome, MD (1)  ·  Katherine A. Price, MD (1)  ·  Kosj Yamoah, M.D., Ph.D. (1)  ·  Michael Schweizer, MD (1)  ·  Ruben Raychaudhuri, MD (1)  ·  Stephen Pautler, MD, FRCSC (1)  ·  Steve Cho, MD (1)

Results publications

PMID 40876952

NIH funding

P30CA014520 (1), P30CA138292 (1), P30CA168524 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186691 (1)